Clinical Research Committee
Janice Lu, MD, PhD
USC Norris Comprehensive Cancer Center
Jun Zhang, MD, PhD
Jun Zhang, MD, PhD, is currently an Assistant Professor and thoracic oncologist at the Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine. Dr. Zhang received his medical degree in Hunan Medical University (now Xiang-Ya School of Medicine, Central South University) and practiced as a pulmonologist in Shanghai Pulmonary Hospital affiliated to Tongji University School of Medicine. This was followed by a PhD training in Louisiana State University in Cancer Biology, as well as postdoctoral training in Dana Farber Cancer Institute of Harvard Medical School and Helen Diller Comprehensive Cancer Center of the University of California San Francisco. To be a physician scientist, he went back to residency training in New York, followed by a Hematology/Oncology training at the Winship Cancer Institute of Emory University School of Medicine. Dr. Zhang is passionate in frontier scientific discoveries and their clinical implications with the focus in lung cancer and other thoracic malignancies.
Andrew X. Zhu, MD, PhD
Dr. Andrew X. Zhu is Professor of Medicine at Harvard Medical School and Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. Aftergraduating from Beijing Medical University, he obtained his PhD from Columbia University. He completed his Residency in Internal Medicine at Yale-New Haven Hospital of Yale School of Medicine, followed by his Hematology-Oncology Fellowship at Memorial Sloan Kettering Cancer Center. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma. The second area is to develop novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma, assess their potential correlation with clinical outcomes and astherapeutic targets, and dissect the molecular mechanisms of drug resistance to targeted therapy.
As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he led early efforts of developing several molecularly targeted and immunotherapy agents in liver cancers and studying the predictive and surrogate circulating and imaging biomarkers. He and his colleagues initially identified the presence of IDH mutations and the resistance mechanism to FGFR inhibitor in cholangiocarcinoma. He is a founding board member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of ASCO and AACR. Dr. Zhu serves on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Cancer Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.